Provectus Biopharmaceuticals, Inc.

Release Summary

PROVECTUS BIOPHARMACEUTICALS SUBMITS PV-10 PHASE 3 MELANOMA PROTOCOL TO FDA

Provectus Biopharmaceuticals, Inc.